Therma Bright Announces Amendments to InStatin & InVixa Acquisitions
Therma Bright Announces Amendments to InStatin & InVixa Acquisitions
InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
InStatin和InVixa正在開發治療新冠肺炎、哮喘和慢性阻塞性肺疾病的新療法
Toronto, Ontario--(Newsfile Corp. - September 27, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announces that it has entered into an amended agreement with respect to its previously announced acquisition with 2740162 Ontario Inc., operating as August Therapeutics ("August") and Ketiko Bio Corp ("Ketiko") (collectively the "Vendors") to acquire a 25% interest in each of InStatin, Inc. ("InStatin") and InVixa, Inc. ("InVixa"), and to acquire an existing option to acquire additional shares in InStatin and InVixa, as more particularly described in the Company's December 1, 2022 press release.
安大略省多倫多--(新聞檔案公司-2023年9月27日)-智慧AcuVid新冠肺炎快速抗原唾液檢測和其他進步診斷和醫療設備技術的開發商Therma Bright Inc.(多倫多證券交易所股票代碼：THRM)(場外交易代碼：THRM)(以下簡稱“Therma”或“公司”)宣佈，它已就之前宣佈的與2740162安大略省公司(“8月”)和Ketiko Bio Corp(“Ketiko”)(統稱“供應商”)的收購達成了一項修訂協定，將分別收購InStatin，Instatin，收購InStatin和InVixa，InInc.(“InStatin”)和InVixa，Inc.(“InVixa”)，並獲得現有選擇權，以獲得InStatin和InVixa的更多股份，如公司2022年12月1日的新聞稿中更詳細地描述。
Under the amended agreement, Therma Bright has agreed to issue 55,000,000 shares to the Vendors (27,500,000 to each of the Vendors) at the market price, in exchange for 4,159,904 shares in the capital of InVixa from Ketiko (representing approximately 61% of the issued and outstanding shares therein), and 520,000 shares in the capital of InStatin (representing approximately 17% of the issued and outstanding shares therein). Additionally an option will provide Therma with the right to purchase up to an additional 577,386 shares in the capital of InStatin in consideration of cash payments of up to $499,997.08.
根據修訂後的協定，Therma Bright同意以市場價格向賣方發行55,000,000股(向每一名賣方27,500,000股)，以換取Ketiko向InVixa發行4,159,904股(約佔其已發行和流通股的61%)和InStatin資本中的520,000股(約佔InStatin已發行和已流通股的17%)。此外，一項選擇權將使Therma有權額外購買InStatin資本中至多577,386股股票，現金支付金額最高可達499,997.08美元。
In connection with the acquisition, the Company shall issue a finder's fee expected to be payable through the issuance of 3,472,222 shares in the Company's capital stock to an arm's length finder for its assistance in sourcing the transaction.
與收購有關，本公司將向公平投資者支付預計將通過發行3,472,222股本公司股本支付的發起人費用，以幫助其尋找交易來源。
The foregoing transaction remains subject to the approval of the TSX Venture Exchange.
上述交易仍有待多倫多證券交易所創業板的批准。
About InVixa
The company is developing inhaled statins to prevent and treat acute lung disease caused by COVID-19. The company is fully focused on the development of novel inhaled therapies for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). For additional information visit .
關於InVixa
該公司正在開發吸入型他汀類藥物，以預防和治療由新冠肺炎引起的急性肺部疾病。該公司完全專注於開發治療新冠肺炎肺炎和急性呼吸窘迫綜合徵的新型吸入療法。有關更多資訊，請訪問。
About InStatin
InStatin is developing novel treatments using inhaled statins for the treatment and management of patients with chronic lung conditions such as asthma and chronic obstructive pulmonary disease ("COPD"). For additional information visit .
關於安裝狀態
InStatin正在開發使用吸入他汀類藥物的新療法，用於治療和管理患有慢性肺部疾病的患者，如哮喘和慢性阻塞性肺疾病(COPD)。有關更多資訊，請訪問。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
關於Therma Bright Inc.
Therma Bright是一家領先的專有診斷和醫療設備技術的開發商和合作夥伴，致力於為消費者和醫療專業人員提供高質量的創新解決方案，以應對當今一些最重要的醫療和保健挑戰。Therma Bright Inc.在多倫多證券交易所(TSXV：THRM)(場外交易市場代碼：TBRIF)(紐約證券交易所代碼：JNX)交易。參觀：。
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Therma Bright Inc.
羅布·菲亞，首席執行官
郵箱：rfia@thermabright.com
Follow us on Twitter
關注我們的推特
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the development of novel treatments to treat COVID-19, Asthma and COPD and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性陳述
本新聞稿中的某些陳述構成“前瞻性”陳述。這些陳述涉及未來事件，例如治療新冠肺炎、哮喘和慢性阻塞性肺病的新療法的開發以及新聞稿中描述的相關技術。所有這些陳述都涉及大量已知和未知的風險、不確定因素和其他因素，這些風險、不確定因素和其他因素可能導致實際結果與這些前瞻性陳述明示或暗示的結果大不相同。前瞻性陳述涉及重大風險和不確定因素，不應被解讀為對未來業績或結果的保證，也不一定是能否實現此類結果的準確跡象。由於幾個因素和風險，實際結果可能與預期大不相同。儘管本新聞稿中包含的前瞻性陳述是基於公司管理層認為本新聞稿發佈之日的合理假設，但公司不能向投資者保證實際結果將與這些前瞻性陳述一致。本新聞稿中包含的前瞻性陳述是自本新聞稿發佈之日起作出的，除非適用的證券法規另有要求，否則公司不會因為新資訊、未來事件或其他原因而更新或修改任何前瞻性陳述的意圖或義務。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。